Pharmaceutics (Aug 2022)

Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue

  • Boris Peklar,
  • Franc Perdih,
  • Damjan Makuc,
  • Janez Plavec,
  • Jérôme Cluzeau,
  • Zoran Kitanovski,
  • Zdenko Časar

DOI
https://doi.org/10.3390/pharmaceutics14081641
Journal volume & issue
Vol. 14, no. 8
p. 1641

Abstract

Read online

Glasdegib is a recently approved drug for the treatment of acute myeloid leukemia. It is formulated and marketed in monomaleate salt form. In our investigation, we were able to prepare a glasdegib dimaleate form, which could, in theory, exist in double-salt form or as a mixture of salt and co-crystal species. Therefore, the obtained crystals of glasdegib dimaleate were characterized via 15N ssNMR and single-crystal X-ray diffraction, which revealed that the obtained glasdegib dimaleate exists in double-salt form. This is a surprising finding based on the pKa values for glasdegib and maleic acid. Furthermore, we fully characterized the new dimaleate form using thermal analyses (DSC and TGA) and spectroscopy (IR and Raman). Finally, the physicochemical properties, such as solubility and chemical stability, of both forms were determined and compared.

Keywords